Skip to main content

Table 4 Comparison of the changes in CMR characteristics of LV by randomization groups

From: Long-term cardiac MRI follow up of MANTICORE (Multidisciplinary Approach to Novel Therapies in Cardio-Oncology REsearch)

 

Overall (N = 52)

Placebo (N = 15)

Perindopril (N = 16)

Bisoprolol (N = 21)

pintercation*

p†

LV EF

    

0.011

 

 Baseline

61.6 ± 4.4

60.9 ± 4.4

62.4 ± 5.3

61.5 ± 3.8

 

0.64

1 year

59.6 ± 5.4

56.5 ± 5.1

60.0 ± 5.9

61.5 ± 4.4||

 

0.019

 Extended FU

58.8 ± 5.3

59.1 ± 4.9

58.4 ± 5.9

58.9 ± 5.2

 

0.94

 Change from baseline to extended FU

-2.8 ± 4.6‡

-1.9 ± 4.1

-4.0 ± 4.6‡

-2.6 ± 4.8‡

 

0.42

 Change from 1 year to extended FU

-0.8 ± 5.3

2.6 ± 5.4

-1.6 ± 3.8

-2.6 ± 5.3||

 

0.010

LV EDV

    

0.75

 

 Baseline

123.6 ± 25.1

130.3 ± 30.4

117.3 ± 20.9

123.7 ± 23.8

 

0.36

 12-month

137.7 ± 26.7

140.9 ± 24.7

135.1 ± 28.2

137.4 ± 27.8

 

0.84

 Extended FU

123.0 ± 25.1

124.8 ± 23.2

120.8 ± 28.2

123.4 ± 24.9

 

0.91

 Change from baseline to extended FU

-0.6 ± 18.2

-5.5 ± 26.6

3.6 ± 14.8

-0.3 ± 12.5

 

0.39

Change from 1 year to extended FU

-14.7 ± 19.0§

-16.1 ± 18.6§

-14.3 ± 22.0§

-14.0 ± 17.6§

 

0.94

LV ESV

    

0.061

 

 Baseline

47.4 ± 10.9

50.8 ± 12.8

44.2 ± 10.4

47.4 ± 9.6

 

0.25

 1 year

56.2 ± 14.5

61.8 ± 14.6

54.8 ± 15.3

53.2 ± 13.2

 

0.19

 Extended FU

50.9 ± 12.6

51.1 ± 11.0

50.9 ± 16.1

50.7 ± 11.1

 

0.999

 Change from baseline to extended FU

3.5 ± 9.0‡

0.3 ± 10.2

6.8 ± 9.0‡

3.3 ± 7.5

 

0.13

 Change from 1 year to extended FU

-5.3 ± 10.8§

-10.7 ± 12.0§

-3.8 ± 9.4

-2.5 ± 9.9

 

0.06

LV mass

    

0.85

 

 Baseline

91.6 ± 15.0

90.5 ± 16.1

92.3 ± 12.5

91.8 ± 16.4

 

0.95

 1 year

92.5 ± 14.5

93.2 ± 15.3

92.1 ± 14.4

92.2 ± 14.6

 

0.97

 Extended FU

65.7 ± 12.7

64.9 ± 14.3

67.0 ± 12.1

65.3 ± 12.4

 

0.89

 Change from baseline to extended FU

-25.9 ± 8.9‡

-25.6 ± 8.9‡

-25.3 ± 9.6‡

-26.5 ± 8.8‡

 

0.92

 Change from 1 year to extended FU

-26.7 ± 9.8§

-28.3 ± 11.4§

-25.1 ± 10.2§

-26.9 ± 8.6§

 

0.66

  1. EF: ejection fraction; EDV: end-diastolic volume; ESV: end-systolic volume; FU: follow-up; LV: left ventricle; pinteracation: p-value for interaction between randomization group and time
  2. *p-value from repeated measures ANOVA
  3. †p-value for one-way ANOVA for comparison between randomization groups
  4. ‡p-value < 0.05 versus baseline
  5. §p-value < 0.05 versus 1 year
  6. ||p-value < 0.05 versus placebo